Effect of Extended Cannabis Abstinence on PTSD Symptoms

Centre for Addiction and Mental Health24 enrolled

Overview

This will be a 12-week randomized trial. Outpatients and patients from the Mood and Anxiety program at the Centre for Addiction and Mental Health (CAMH) with a current diagnosis of post-traumatic stressed disorder (PTSD) and cannabis-use disorder (CUD) will be randomized to receive individual motivational interviewing therapy and contingency management (n = 12) or individual motivational interviewing therapy alone (control group, n = 12) after enrolment.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

OTHER

Masking

NONE

Enrollment

Conditions

PTSD Cannabis Use Cognitive Symptom Comorbidities and Coexisting Conditions

Interventions

Contingency-managementBEHAVIORAL

In addition to structured assessments at baseline, four, eight and twelve months, subjects randomized to the contingency-management group will receive a contingent bonus if the participants show successful abstinence at the end of weeks 4, 8 and 12.

Enhanced usual careOTHER

Subjects will receive structured, quantitative assessments at baseline, four, eight and twelve weeks.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 55 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Subjects aged between 18 and 55 years (from both sexes \[or genders\]); 2. Diagnosed with CUD (moderate or severe) according to the Structured Clinical Interview for DSM-IV (SCID) (mode of cannabis consumption can be inhalation or ingestion); 3. Diagnosis of current (past 30 days) PTSD, using the CAPS-5 on screening; 4. On antidepressant medication(s) for at least 1 month (to ensure safety and homogeneity as PTSD treatment of our population); 5. Be able to provide written informed consent; and 6. Be able to communicate in English. Exclusion Criteria: 1. diagnosed with a severe or unstable medical illness that precludes safe participation in the study as per the study physician; 2. diagnosed with schizophrenia, schizoaffective disorder, or bipolar disorder or current acute psychosis or mania based on DSM-5 criteria; 3. current suicidality risk as indicated by the Columbia Suicide Severity Rating Scale (C-SSRS) with concurrence after the study physician's evaluation if the response to C-SSRS questions 1 or 2 is "yes" 34; and 4. have pain interfering with normal function as reported by the 12-Item Short Form Survey (SF-12) (moderate or higher interference).

Locations (1)

Centre for Addiction and Mental Health

Toronto, Ontario, Canada

RECRUITING

Outcomes

Primary Outcomes

Severity of PTSD symptoms, as measured with the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) at week 4

Changes in CAPS-5 during the study phase between the group that achieved abstinence and the group that did not. In addition, we will record changes in each PTSD symptom category, which will all be part of the larger trial analysis.

Time frame: Week 0-4

Secondary Outcomes

Changes in cognitive function, as measured with various Cambridge Automated Neuropsychological Test Automated Battery (CANTAB) cognitive tests

Changes between abstainers and non-abstainers on cognitive testing during the study phase.

Time frame: Week 0-4

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.